TheStreet

Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Already have an account? Login here
TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

SUBSCRIBE NOW

LATEST NEWS

Chinese Biotech Start-up Antengene Plans Hong Kong IPO, Targeting Gaps In Treatment Of Prevalent Asian Cancers
Play
INVESTING

Acceleron Soars in After-Hours Trading on Positive Trial Results for Hypertension Treatment

  • By Tom Bemis
  • Jan 27, 2020 5:37 PM EST
PRESS RELEASES

Nektar Appoints Dr. Brian Kotzin As Interim Chief Medical Officer And Head Of Development

  • By PR Newswire
  • Jan 5, 2021 4:20 PM EST
PRESS RELEASES

Nektar Therapeutics Announces Agreement With Healthcare Royalty To Sell ADYNOVATE® And MOVANTIK® Royalties For $150 Million

  • By PR Newswire
  • Dec 22, 2020 8:30 AM EST
PRESS RELEASES

Nektar Therapeutics Announces Dosing Of First Patients In Phase 1/2 Study Of Its IL-15 Agonist, NKTR-255, In Combination With Cetuximab In Patients With Head And Neck Squamous Cell Carcinoma Or Colorectal Cancer

  • By PR Newswire
  • Dec 15, 2020 8:30 AM EST
PRESS RELEASES

Nektar Therapeutics Announces Presentation Of Preclinical Data For NKTR-255, Its Novel IL-15 Agonist, At The American Society Of Hematology (ASH) 2020 Annual Meeting

  • By PR Newswire
  • Dec 7, 2020 4:00 PM EST
PRESS RELEASES

New Clinical Data Presented From Phase 1b Study Of NKTR-358, A Novel T Regulatory Cell Stimulator, At 2020 American College Of Rheumatology (ACR) Congress

  • By PR Newswire
  • Nov 4, 2020 10:15 AM EST
PRESS RELEASES

Nektar Therapeutics To Host Webcast Conference Call For Analysts & Investors For 2020 American College Of Rheumatology (ACR) Congress

  • By PR Newswire
  • Oct 29, 2020 6:00 PM EDT
PRESS RELEASES

Nektar To Announce Financial Results For The Third Quarter 2020 On Thursday, November 5, 2020, After Close Of U.S.-Based Financial Markets

  • By PR Newswire
  • Oct 28, 2020 6:00 PM EDT
PRESS RELEASES

Nektar To Announce Financial Results For The Second Quarter 2020 On Thursday, August 6, 2020, After Close Of U.S.-Based Financial Markets

  • By PR Newswire
  • Jul 28, 2020 6:00 PM EDT
PRESS RELEASES

Data Presented From Phase 1b Study Of NKTR-358, A Novel T Regulatory Cell Stimulator, At Annual European Congress Of Rheumatology (EULAR 2020)

  • By PR Newswire
  • Jun 4, 2020 5:00 PM EDT
PRESS RELEASES

Nektar Therapeutics To Host Webcast Conference Call For Analysts & Investors During 2020 Virtual European Congress Of Rheumatology (EULAR 2020)

  • By PR Newswire
  • May 29, 2020 5:00 PM EDT
PRESS RELEASES

Nektar Therapeutics Announces Publication Of Results From Phase 1 Dose-Escalation Study For Bempegaldesleukin Plus Nivolumab In 'Cancer Discovery' Journal

  • By PR Newswire
  • May 22, 2020 8:30 AM EDT
PRESS RELEASES

Nektar To Announce Financial Results For The First Quarter 2020 On Thursday, May 7, 2020, After Close Of U.S.-Based Financial Markets

  • By PR Newswire
  • Apr 28, 2020 5:00 PM EDT
PRESS RELEASES

Nektar Therapeutics To Webcast Presentation At The Cowen And Company 40th Annual Health Care Conference

  • By PR Newswire
  • Feb 28, 2020 6:30 PM EST
PRESS RELEASES

Nektar To Announce Financial Results For The Fourth Quarter And Year-Ended 2019 On Thursday, February 27, 2020, After Close Of U.S.-Based Financial Markets

  • By PR Newswire
  • Feb 18, 2020 5:00 PM EST
PRESS RELEASES

Nektar Therapeutics Announces Publication Of Two Manuscripts On Lead Immuno-oncology Candidate, Bempegaldesleukin (Bempeg) In Nature Communications

  • By PR Newswire
  • Feb 3, 2020 8:00 AM EST
Chinese Biotech Start-up Antengene Plans Hong Kong IPO, Targeting Gaps In Treatment Of Prevalent Asian Cancers
INVESTING

Acceleron Soars in After-Hours Trading on Positive Trial Results for Hypertension Treatment

  • By Tom Bemis
  • Jan 27, 2020 5:37 PM EST
PRESS RELEASES

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Nektar Therapeutics - NKTR

  • By PR Newswire
  • Jan 24, 2020 7:02 PM EST
Nektar Squeezed as FDA Rejects Opioid Addiction
Video

Nektar Still Has Some Juice

  • Jan 15, 2020 10:03 AM EST
Merck Wins Drug Approval and Part of a Court Case; Here's How to Trade the Stock
INVESTING

Nektar Squeezed as FDA Rejects Opioid Addiction-Fighting Drug

  • By M. Corey Goldman
  • Jan 15, 2020 9:44 AM EST
PRESS RELEASES

Nektar Issues Statement Regarding FDA Advisory Committee Vote For Oxycodegol

  • By PR Newswire
  • Jan 14, 2020 10:47 PM EST
PRESS RELEASES

Shareholder Alert: Robbins LLP Reminds Investors Nektar Therapeutics (NKTR) Sued For Misleading Shareholders

  • By Business Wire
  • Jan 10, 2020 2:32 PM EST
Nektar Is the One S&P 500 Company Without a Woman Director
INVESTING

Nektar Therapeutics, Bristol-Myers Expand Effort to Develop Treatment for Cancer

  • By Dan Weil
  • Jan 10, 2020 1:01 PM EST
PRESS RELEASES

Nektar Therapeutics' President And CEO, Howard Robin, To Present At The 38th Annual J.P. Morgan Healthcare Conference In San Francisco, CA

  • By PR Newswire
  • Jan 7, 2020 9:00 AM EST
Nektar Is the One S&P 500 Company Without a Woman Director
INVESTING

Nektar Shares Drop After Double Downgrade to Sell at Goldman Sachs

  • By M. Corey Goldman
  • Oct 8, 2019 5:12 PM EDT
TheStreet
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.